Industrializing organoids for drug discovery
Rosebud Biosciences is an early-stage biotech startup that models human genetic diseases using iPSC-derived organoids to discover and screen drugs for rare pediatric conditions. Their automated platform predicts drug efficacy and screens for off-target toxicities entirely in human tissue models, accelerating translational drug development. Founded in 2020 and backed by Y Combinator, the company targets the 95% of genetic diseases that still lack approved treatments.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Databricks is the pioneer of the data lakehouse, a unified platform for data science, machine lea...
For more than 30 years, BMC has helped thousands of companies around the world master IT complexi...
Quest Software (Nasdaq: QSFT) is a provider of application and information availability software ...
AI-powered customer experience and contact center platform serving enterprises globally.
Udemy is a global marketplace for online education that is constantly growing and evolving. The c...
